amylin/GLP-1 combinationGLP-1 Agonists
CagriSema
A combination of cagrilintide (long-acting amylin analog) and semaglutide. Phase 3 REDEFINE-1 showed 20.4% weight loss. NDA submitted December 2025. Combines two complementary appetite-regulating pathways.
weight-lossappetite-suppressioncombination-therapyexperimental
3D Structure
3D Structure
Lab Tested
No
Harmful Ingredients
0
Contaminants
None
Tested Purity
--
Batch Consistency
No batch data
Mass Spec Profile
No mass spec data
Batch Info
Latest Batch—
Total Tests0
Unique Vendors0
Vendor Comparison
No vendor data yet
Analysis Summary
Purity Standard
No purity dataLab Reports
0 reports on file
Summary
A combination of cagrilintide (long-acting amylin analog) and semaglutide. Phase 3 REDEFINE-1 showed 20.4% weight loss. NDA submitted December 2025. Combines two complementary appetite-regulating path…